A new treatment for polycystic kidney disease, Jinarc (tolvaptan), has been recommended for approval by the European Medicines Agency. Developed by Otsuka Pharmaceutical Co, Jinarc is designed to treat a rare, inherited form of the disorder that affects about four in 10,000 people in the EU.
